Laser Immunotherapy (LIT) is a new approach for cancer treatment using host immune system to fight the disease. Laser Immunotherapy provides a convenient, efficient means to directly destroy the tumors at the treatment site and to induce tumor-specific host immune responses. LIT utilizes a near-infrared laser, a light-absorbing agent, and an immunoadjuvant for the selective photothermal interaction and the targeted immunological stimulation.

Laser Immunotherapy Treatment for Late-stage CancerThermal therapy has been used for cancer treatment for more than a century. While thermal effect can be direct, immediate, and controllable, it is not sufficient to completely eradicate tumors, particularly when tumors have metastasized locally or to the distant sites. Metastases are the major cause of treatment failure and cancer deaths. Current available therapies, such as surgery, radiation, and chemotherapy, only have limited curative effects in patients with late-stage, metastatic cancers.

Laser Immunotherapy has been considered as the ultimate approach for cancer treatment since a systemic, anti-tumor, immunological response can be induced. Using the combination of photothermal therapy and immunotherapy, laser immunotherapy (LIT), a novel immunotherapy modality for late-stage cancer treatment, has been developed.

Laser Immunotherapy (LIT) has shown great promise in pre-clinical studies and clinical breast cancer and melanoma pilot trials. However, the skin color and the depth of the tumor have been challenges for effective treatment with LIT. To induce a thermal destruction zone of appropriate size without causing thermal damage on the skin, biomedical researchers have developed interstitial laser immunotherapy (ILIT) using a cylindrical diffuser.